Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: A 72-week prospective multicenter study (TENOR-trial)

European Journal of Medical Research

Volumn 14, Issue 12, 2009, Pages 516-519

  Weberschock, Tanja ^a   Gholam, P ^a   Hueter, E ^a   Flux, K ^a   Hartmann, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ART; Emtricitabine; Nevirapine; Once daily; Tenofovir; Treatment efficacy

Indexed keywords

EMTRICITABINE; NEVIRAPINE; TENOFOVIR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; SIDE EFFECT; VIRUS LOAD;

EID: 75149128106     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-14-12-516     Document Type: Article

References (12)

1. Gifford AL, Bormann JE, Shivley MJ, et al. Predictors of selfreported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23: 386-95
2. Ammassari A, Murri R, Pezzotti P, et al. Self-reported Symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001; 28: 445-9.
3. Trotta MP, Ammassari A, Melzi S, et al. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002; 15: 31(suppl 3), S128-131.
4. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 2005;5:185-190.
5. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: Survey of women in the HER study. J Acquir Immune Defic Syndr. 2001;28:124-131.
6. Cooper CL, van Heeswijk RP. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Med. 2007; 8: 1-7.
7. Van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FWNM, Lange JMA, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RMW. AIDS. 2000; 14: 8,F77-F82.
8. Kappelhoff BS, Huitema AD, van Leth F, Robinson PA, MacGregor TR, Lange JM, Beijnen JH; 2NN Study Group. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clin Trials. 2005;6:254-261.
9. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der West-huizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM; 2NN Study team. Lancet. 2004; 17;363(9417):1253-63
10. Keiser P, Nassar N, Yazdani B, Armas L, Moreno S. HIV Clin. Trials. 2003; 4(5): 358-360.
11. Clotet B. Once-daily dosing of nevirapine in HAART. J Antimicrob Chemother. 2008; 61: 13-16.
12. Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004535